Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Yujie Ren in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Xue Han in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Yujiang Li in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Key Laboratory of TCM Syndrome and Treatment of Yingbing (Thyroid Disease) of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Guofang Chen in
Google Scholar
PubMed
Search for other papers by Lin Jiang in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Key Laboratory of TCM Syndrome and Treatment of Yingbing (Thyroid Disease) of State Administration of Traditional Chinese Medicine, Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Chao Liu in
Google Scholar
PubMed
Jiangsu Province Academy of Traditional Chinese Medicine, Nanjing, China
Search for other papers by Shuhang Xu in
Google Scholar
PubMed
are diagnosed as PTMCs ( 5 ). Thyroid cancer is characterized by a favorable prognosis and low tumor-specific mortality ( 6 ). Low-risk PTMC patients usually have an acceptable prognosis, with 10-year and 15-year survivals of 94.6% and 90
Center for International Health, University of Bergen, Bergen, Norway
Search for other papers by Kjersti S Bakken in
Google Scholar
PubMed
Department of Microbiology, Innlandet Hospital Trust, Lillehammer, Norway
Search for other papers by Kristina Randjelovic Nermo in
Google Scholar
PubMed
Department of Clinical Science, University of Bergen, Bergen, Norway
Search for other papers by Bjørn Gunnar Nedrebø in
Google Scholar
PubMed
Search for other papers by Tim I M Korevaar in
Google Scholar
PubMed
Department of Research, Innlandet Hospital Trust, Lillehammer, Norway
Search for other papers by Tor A Strand in
Google Scholar
PubMed
birth. This variable was missing for 28,337 pregnancies (3.2%). The number of pregnancies each year varied from 54,292 in 2018 to 59,307 in 2010. During 2004–2018, the mean maternal age increased from 29.6 to 30.5 years ( Table 1 ). Figure 1
Search for other papers by Alexander Heinzel in
Google Scholar
PubMed
Search for other papers by Dirk Müller in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by Hanneke M van Santen in
Google Scholar
PubMed
Emma Children’s Hospital, Amsterdam UMC, Department of Pediatrics, Amsterdam, The Netherlands
Search for other papers by Sarah C Clement in
Google Scholar
PubMed
Search for other papers by Arthur B Schneider in
Google Scholar
PubMed
University Hospital Würzburg, Department of Nuclear Medicine, Würzburg, Germany
Search for other papers by Frederik A Verburg in
Google Scholar
PubMed
.4% at a tumor diameter of 1.1 cm, 4.8 ± 1.1% at 2.5 cm and 13.1 ± 2.5% at 4.1 cm. For patients without distant metastases and >18 and <45 years of age at diagnosis, 10-year survival was 98.4 ± 0.5%. For patients <45 years of age with distant metastases
Search for other papers by Yuegui Wang in
Google Scholar
PubMed
Search for other papers by Liwei Hong in
Google Scholar
PubMed
School of Clinical Medicine, Fujian Medical University, Fuzhou, Fujian, China
Search for other papers by Caiyun Yang in
Google Scholar
PubMed
Quanzhou Medical College, Quanzhou, Fujian, China
Search for other papers by Guorong Lv in
Google Scholar
PubMed
Search for other papers by Kangjian Wang in
Google Scholar
PubMed
Search for other papers by Xuepeng Huang in
Google Scholar
PubMed
Search for other papers by Haolin Shen in
Google Scholar
PubMed
orbitopathy ( 5 ). Therapies for GD include antithyroid drugs (ATDs), thyroidectomy, or radioactive iodine (RAI) therapy. ATD has only a 50% success rate for most patients after 1 year of treatment, and it may cause side effects such as agranulocytosis
Search for other papers by Bogumila Urgatz in
Google Scholar
PubMed
Search for other papers by Kris G Poppe in
Google Scholar
PubMed
more than 70%, relative to the use of 2.5 μIU/mL as the cut-off value, with no change relative to the institutional cut-off value ( 17 ). Thus, rigid adherence to low cut-off values for TSH in diagnosing SCH may be inappropriate, with risk of missing
Search for other papers by Teresa Kraus in
Google Scholar
PubMed
Search for other papers by Natalia Shengelia-de Lange in
Google Scholar
PubMed
Search for other papers by Holger Einspieler in
Google Scholar
PubMed
Search for other papers by Marcus Hacker in
Google Scholar
PubMed
Search for other papers by Alexander Haug in
Google Scholar
PubMed
Search for other papers by Elisabeth Kretschmer-Chott in
Google Scholar
PubMed
Search for other papers by Georgios Karanikas in
Google Scholar
PubMed
studies should be performed ( 10 , 11 ). The American Thyroid Association (ATA) states that a diagnostic WBS 1 year after radioiodine ablation is not required in low- and intermediate-risk patients. Instead, the ATA recommends serum Tg assays, serum Tg
Search for other papers by Yanling Cai in
Google Scholar
PubMed
Search for other papers by Yan Yang in
Google Scholar
PubMed
Search for other papers by Xiao Pang in
Google Scholar
PubMed
Search for other papers by Suping Li in
Google Scholar
PubMed
the rate of local recurrence after thyroidectomy or subtotal thyroidectomy in patients with DTC and can significantly improve the 10-year survival rate in patients with DTC. Studies have shown that the 5-year survival rate of patients with papillary
Search for other papers by Sandeep Kumar Parvathareddy in
Google Scholar
PubMed
Search for other papers by Abdul K Siraj in
Google Scholar
PubMed
Search for other papers by Zeeshan Qadri in
Google Scholar
PubMed
Search for other papers by Saeeda O Ahmed in
Google Scholar
PubMed
Search for other papers by Felisa DeVera in
Google Scholar
PubMed
Search for other papers by Saif Al-Sobhi in
Google Scholar
PubMed
Search for other papers by Fouad Al-Dayel in
Google Scholar
PubMed
Search for other papers by Khawla S Al-Kuraya in
Google Scholar
PubMed
.6 No 941 79.4 Recurrence Yes 275 19.5 No 1132 80.5 ATA risk category Low 231 16.4 Intermediate 460 32.7 High 716 50.9 Lymph node ratio cut-off LNR was
Search for other papers by Rasmus Reinke in
Google Scholar
PubMed
Search for other papers by Stefano Christian Londero in
Google Scholar
PubMed
Search for other papers by Martin Almquist in
Google Scholar
PubMed
Search for other papers by Lars Rejnmark in
Google Scholar
PubMed
Search for other papers by Lars Rolighed in
Google Scholar
PubMed
) or their vascular supply ( 3 ). HypoPT may reduce quality of life ( 4 ) and increases both mortality ( 5 ) and morbidity ( 6 ). Morbidity for patients with hypoPT includes an increased risk of developing chronic kidney disease (CKD) and kidney
Department of Pediatric Endocrinology, Wilhelmina Children’s Hospital/ University Medical Center Utrecht, Utrecht, The Netherlands
Search for other papers by S C Clement in
Google Scholar
PubMed
Search for other papers by W E Visser in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by C A Lebbink in
Google Scholar
PubMed
Search for other papers by D Albano in
Google Scholar
PubMed
Search for other papers by H L Claahsen-van der Grinten in
Google Scholar
PubMed
Search for other papers by A Czarniecka in
Google Scholar
PubMed
Institute of Metabolism and Systems Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham, UK
Search for other papers by R P Dias in
Google Scholar
PubMed
Search for other papers by M P Dierselhuis in
Google Scholar
PubMed
Search for other papers by I Dzivite-Krisane in
Google Scholar
PubMed
Search for other papers by R Elisei in
Google Scholar
PubMed
Search for other papers by A Garcia-Burillo in
Google Scholar
PubMed
Search for other papers by L Izatt in
Google Scholar
PubMed
Search for other papers by C Kanaka-Gantenbein in
Google Scholar
PubMed
Search for other papers by H Krude in
Google Scholar
PubMed
Search for other papers by L Lamartina in
Google Scholar
PubMed
Search for other papers by K Lorenz in
Google Scholar
PubMed
Search for other papers by M Luster in
Google Scholar
PubMed
Search for other papers by R Navardauskaitė in
Google Scholar
PubMed
Search for other papers by M Negre Busó in
Google Scholar
PubMed
Search for other papers by K Newbold in
Google Scholar
PubMed
Search for other papers by R P Peeters in
Google Scholar
PubMed
Search for other papers by G Pellegriti in
Google Scholar
PubMed
Search for other papers by A Piccardo in
Google Scholar
PubMed
Search for other papers by A L Priego in
Google Scholar
PubMed
Search for other papers by A Redlich in
Google Scholar
PubMed
Search for other papers by L de Sanctis in
Google Scholar
PubMed
Search for other papers by M Sobrinho-Simões in
Google Scholar
PubMed
Search for other papers by A S P van Trotsenburg in
Google Scholar
PubMed
Search for other papers by F A Verburg in
Google Scholar
PubMed
Search for other papers by M Vriens in
Google Scholar
PubMed
Search for other papers by T P Links in
Google Scholar
PubMed
Developmental Endocrinology Research Group, Royal Hospital for Children, University of Glasgow, Glasgow, UK
Office for Rare Conditions, University of Glasgow, Glasgow, UK
Search for other papers by S F Ahmed in
Google Scholar
PubMed
Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
Search for other papers by H M van Santen in
Google Scholar
PubMed
consultation at year 2 (T3), year 5 (T4), and year 10 (T5). A summary of the study design is outlined in Table 1 . Table 1 Registry activities. Registry period Enrollment and entry of baseline data Follow-up Early termination